ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]
This is an exciting addition to my recent interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.
MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]
We’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think?
CellPlan Launches The World’s First Global Stem Cell Healthcare Plan
CellPlan today announced the creation of the world’s first global stem cell healthcare plan, which will be launched at the World Cord Blood Congress Europe 2016 in London this month. The UK company said that the new medical insurance product could revolutionize stem cell healthcare by making stem cell transplants affordable for families who require treatment for life threatening diseases. [Read more…]
After sponsoring Cord Blood World Europe in 2015, BioInformant is honored to announce that we are continuing our sponsorship for the 2016 event, held over May 18-19, 2016, at the London Business Design Centre, in London, UK.
As the first and only company to exclusively track stem cell markets, BioInformant has released a 204 page eport about the gord blood banking industry, covers breaking cord blood news on our blog, and has a partnership with the Save the Cord Foundation, titled “Cord Blood Banking Awareness: Educating America and the World.” The campaign is a global effort to educate currently expecting parents, as well as future parents, grandparents, siblings, and friends about the medical benefits of cord blood preservation.
BioInformant is deeply committed to advancing progress with cord blood, because cord blood contains valuable hematopoietic stem cells and cord tissue (“Wharton’s jelly”) contains valuable mesenchymal stem cells.